Select Publications
Journal articles
2024, 'Cardiac magnetic resonance imaging in the diagnosis of cardiac tumours', European Heart Journal Cardiovascular Imaging, 25, pp. e273, http://dx.doi.org/10.1093/ehjci/jeae205
,2024, 'Promoting physical activity among cancer survivors through general practice: a realist review.', Fam Pract, http://dx.doi.org/10.1093/fampra/cmae053
,2024, 'Sharing Colorectal Cancer Follow-Up Using an E-Care Plan Between Cancer Services and Primary Health Care', Studies in Health Technology and Informatics, 310, pp. 1517 - 1518, http://dx.doi.org/10.3233/SHTI231272
,2024, 'Kiosk 9Q-FA-02 Utility of CMR in Diagnosis of Metastatic Cardiac Melanoma', Journal of Cardiovascular Magnetic Resonance, 26, pp. 100930, http://dx.doi.org/10.1016/j.jocmr.2024.100930
,2023, 'Improving Medication Safety in Cancer Services for Ethnic Minority Consumers: Protocol for a Pilot Feasibility and Acceptability Study of a Co-Designed Consumer Engagement Intervention', JMIR Research Protocols, 12, pp. e49902, http://dx.doi.org/10.2196/49902
,2023, 'Making it Meaningful : Co-designing an intervention to improve medication safety for people from culturally and linguistically diverse backgrounds accessing cancer services', Patient Experience Journal, 10, pp. 34 - 48, http://dx.doi.org/10.35680/2372-0247.1732
,2022, 'Durvalumab and multimodality therapy in a patient with multiple recurrent and unresectable cutaneous squamous cell carcinoma', Internal Medicine Journal, 52, pp. 1103 - 1104, http://dx.doi.org/10.1111/imj.15809
,2022, 'What does co-design mean for Australia's diverse clinical workforce?', Australian Health Review, 46, pp. 60 - 61, http://dx.doi.org/10.1071/AH21116
,2021, 'Codesigning consumer engagement strategies with ethnic minority consumers in Australian cancer services: The CanEngage Project protocol', BMJ Open, 11, pp. e048389, http://dx.doi.org/10.1136/bmjopen-2020-048389
,2021, 'Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice', Public Health Research and Practice, 31, http://dx.doi.org/10.17061/PHRP31122108
,2021, 'Standard-dose osimertinib in egfr-mutated non-small-cell lung adenocarcinoma with leptomeningeal disease', JCO Precision Oncology, 5, pp. 561 - 568, http://dx.doi.org/10.1200/PO.20.00464
,2020, 'Assessing suitability for long-term colorectal cancer shared care: a scenario-based qualitative study', BMC Family Practice, 21, pp. 240, http://dx.doi.org/10.1186/s12875-020-01311-w
,2020, 'Correlation between initial tumour volume and treatment duration on Dabrafenib: Observation study of subjects with BRAF mutant melanoma on the BRF112680 trial', BMC Cancer, 20, pp. 342, http://dx.doi.org/10.1186/s12885-020-06848-8
,2019, 'Development of an interactive, web-based shared care plan to facilitate the follow-up care of colorectal cancer patients', , http://dx.doi.org/10.21203/rs.2.13454/v2
,2019, '“Can I still get a tattoo?” Patients’ experiences across the clinical trajectory for metastatic melanoma: a dynamic narrative model of patient journey', Patient Experience Journal, 6, pp. 87 - 93, http://dx.doi.org/10.35680/2372-0247.1301
,2018, 'Using behaviour change and implementation science to address low referral rates in oncology', BMC Health Services Research, 18, pp. 904, http://dx.doi.org/10.1186/s12913-018-3653-1
,2018, 'The plot thickens: Archetypal narrative structure in the melanoma patient journey', Critical Public Health, 5, pp. 1484053, http://dx.doi.org/10.1080/2331205x.2018.1484053
,2017, 'Advanced cancer patients’ attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study', European Journal of Cancer Care, 26, http://dx.doi.org/10.1111/ecc.12600
,2017, 'Patient, general practitioner and oncologist views regarding long-term cancer shared care.', Fam Pract, 35, pp. 323 - 329, http://dx.doi.org/10.1093/fampra/cmx105
,2017, 'Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy', Kidney and Blood Pressure Research, 42, pp. 62 - 75, http://dx.doi.org/10.1159/000469715
,2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015
,2016, 'Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: A case report', BMC Research Notes, 9, pp. 386, http://dx.doi.org/10.1186/s13104-016-2189-x
,2016, 'Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer', Oncology and Therapy, 4, pp. 103 - 116, http://dx.doi.org/10.1007/s40487-016-0020-4
,2016, 'The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study', ONCOLOGIST, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530
,2016, 'The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: An Australian population-based multicenter study', Oncologist, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530
,2016, 'Achieving behaviour change for detection of Lynch syndrome using the Theoretical Domains Framework Implementation (TDFI) approach: A study protocol', BMC Health Services Research, 16, pp. 89, http://dx.doi.org/10.1186/s12913-016-1331-8
,2016, '198P Use of chemotherapy and mismatch repair deficiency testing in resected stage II colon cancer', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw581.031
,2015, 'TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.', Journal of Clinical Oncology, 33, pp. 9571 - 9571, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9571
,2014, 'Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)', Clinical Cancer Research, 20, pp. 4449 - 4458, http://dx.doi.org/10.1158/1078-0432.CCR-14-0887
,2014, 'Cutaneous metastasis of prostate carcinoma treated with radiotherapy: A case presentation', BMC Research Notes, 7, pp. 505, http://dx.doi.org/10.1186/1756-0500-7-505
,2014, 'Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment', Melanoma Research, 24, pp. 408 - 412, http://dx.doi.org/10.1097/CMR.0000000000000085
,2014, 'Targeting treatment for colorectal cancer: The EGFR antibody story', Cancer Forum, 38, pp. 39 - 43
,2013, 'PLASMA CYSTATIN C IS ELEVATED IN THE ABSENCE OF ACUTE KIDNEY INJURY FOLLOWING CISPLATIN WITH CONTEMPORARY ANTIEMETICS', NEPHROLOGY, 18, pp. 41 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323453000103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Use of neostigmine in capecitabine-induced paralytic ileus', Tumori, 99, http://dx.doi.org/10.1177/030089161309900518
,2013, 'Use of neostigmine in capecitabine-induced paralytic ileus', Tumori Journal, 99, pp. e225 - e228, http://dx.doi.org/10.1177/030089161309900518
,2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585
,2010, 'Phase i clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer', Cancer Chemotherapy and Pharmacology, 65, pp. 597 - 605, http://dx.doi.org/10.1007/s00280-009-1157-8
,2010, 'Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer', Cancer Chemotherapy and Pharmacology, 65, pp. 597 - 605, http://dx.doi.org/10.107/s00280-009-1157-8
,2010, 'Rationale for treatment durations of targeted cancer agents', Lancet Oncology, 11, pp. 1113 - 1115, http://dx.doi.org/10.1016/S1470-2045(10
,2006, 'Primary pancreatic lymphoma - pancreatic tumours that are potentially curable without resection, a retrospective review of four cases', BMC Cancer, 6, pp. 117, http://dx.doi.org/10.1186/1471-2407-6-117
,1998, 'Lipid lowering therapy in patients with HIV infection (multiple letters) [3]', Lancet, 352, pp. 1782 - 1783, http://dx.doi.org/10.1016/s0140-6736(05)79858-5
,Conference Papers
2017, 'Compassionate Supply of Oncology Drugs Within the South Eastern Sydney Local Health District (SESLHD) in 2011-2015', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 188 - 188, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500311&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue', Chicago, presented at 2015 ASCO Annual Meeting, Chicago, 29 May 2015 - 02 June 2015
,2013, 'BARRIERS TO RECRUITMENT FOR A POST-CANCER FATIGUE INTERVENTION STUDY - THE TOPS TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 116 - 116, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours', in Journal of clinical oncology - official journal of the American Society of Clinical Oncology, American Society of Clinical Oncology, New York, pp. e13585 - e13585, presented at ASCO Annual Meeting, Chicago, USA, 01 June 2012 - 05 June 2012, http://meeting.ascopubs.org/gca?gca=ascomtg%3B30%2F15_suppl%2Fe13585&allch=&submit=Go#abstr-1
,2011, 'Describing treatment, treatment outcomes, resource use and quality of life of advanced NSCLC patients – the Lung Cancer Economics and Outcomes Research (LUCEOR) studies.', in Journal of Thoracic Oncology, Lippincott Williams & Wilkins, USA, pp. 1404 - 1405, presented at Proceedings of the 14th World Conference on Lung Cancer, Amsterdam, http://dx.doi.org/10.1097/01.JTO.0000399290.73317.eb
,2009, 'The Financially Tolerable Dose: A New Concept in Cancer Trial Design', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S173 - S174
,Conference Posters
2023, 'Sharing care between specialist health services and primary health care using interactive e-care plans', Online, presented at Digital Health Forum, Online, 07 February 2023
,2021, 'Telemedicine in the context of Covid-19: A qualitativestudy of cancer patients and clinicians', presented at Clinical Oncology Society Australia Annual Scientific Meeting, 16 November 2021
,2020, 'Retrospective analysis of chemotherapy‐induced febrile neutropenia; Local experience towards risk‐based management', Virtual, Vol. 16, pp. 142 - 142, presented at Clinical Oncology Society Australia Annual Scientific Meeting, Virtual, 11 November 2020 - 13 November 2020, http://dx.doi.org/10.1111/ajco.13498
,